Sangretech Biomedical

Sangretech Biomedical is a clinical-stage medical technology company specializing in the development of advanced extracorporeal blood purification systems. The company's core technology is designed to selectively remove harmful pathogens and pro-inflammatory cytokines, such as Interleukin-6, from the bloodstream of patients suffering from life-threatening conditions. Its primary focus is on treating sepsis and the 'cytokine storm' associated with severe viral infections, including COVID-19. By reducing the systemic inflammatory load, Sangretech's device aims to prevent multi-organ failure and improve survival rates in intensive care settings. The company operates as a private entity, advancing its proprietary filtration platform through clinical evaluation and regulatory pathways.